Levothyroxine sodium tablets are indicated for replacement therapy in adult and pediatric patients with hypothyroidism, including congenital or acquired forms. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. The mechanism of action involves the hormone’s control of DNA transcription and protein synthesis, with triiodothyronine (T3) predominantly derived from L-thyroxine (T4) through deiodination.
Pharmacokinetic Properties
Oral levothyroxine sodium is a synthetic T4 hormone that maintains normal T4 levels when a deficiency is present. Absorption ranges from 40% to 80%, influenced by factors like fasting, malabsorption syndromes, and dietary fiber. Pharmacokinetics demonstrate that circulating thyroid hormones are primarily bound to plasma proteins, with T4 exhibiting higher serum levels and a longer half-life. Distribution is greater than 99% bound to TBG, TBPA, and albumin.
Metabolic Elimination
Elimination primarily occurs through metabolism, with approximately 80% of T4 being deiodinated to T3 and reverse T3. This process occurs predominantly in the liver, with secondary sites including the kidney. The major pathway involves sequential deiodination, followed by conjugation with glucuronides and sulfates, and excretion via bile and enterohepatic recirculation. Dosage is typically once daily on an empty stomach, at least 4 hours before interfering drugs. Starting doses vary based on patient factors, and therapeutic effect may take 4-6 weeks to achieve. Monitoring of TSH and/or T4 levels, along with clinical status, is essential for adequacy of therapy. Patients should avoid biotin supplements during TSH/T4 assessment.